Dr. Reddy’s announces the Launch of Paricalcitol Capsules
HYDERABAD, India -- June 25, 2014
Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched
Paricalcitol Capsules, 1 mcg, 2 mcg and 4 mcg, a therapeutic equivalent
generic version of ZEMPLAR^® (Paricalcitol) Capsules in the US market on June
24, 2014, following the approval by the United States Food & Drug
The ZEMPLAR^® brand and generic had U.S. sales of approximately $109.6 Million
MAT for the most recent twelve months ending in March 2014 according to IMS
Dr. Reddy’s Paricalcitol Capsules 1 mcg, 2 mcg and 4 mcg are available in
bottle counts of 30.
This press release includes forward-looking statements, as defined in the U.S.
Private Securities Litigation Reform Act of 1995. We have based these
forward-looking statements on our current expectations and projections about
future events. Such statements involve known and unknown risks, uncertainties
and other factors that may cause actual results to differ materially. Such
factors include, but are not limited to, changes in local and global economic
conditions, our ability to successfully implement our strategy, the market
acceptance of and demand for our products, our growth and expansion,
technological change and our exposure to market risks. By their nature, these
expectations and projections are only estimates and could be materially
different from actual results in the future.
About Dr. Reddy’s
Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global
pharmaceutical company, committed to providing affordable and innovative
medicines for healthier lives. Through its three businesses - Pharmaceutical
Services and Active Ingredients, Global Generics and Proprietary Products –
Dr. Reddy’s offers a portfolio of products and services including APIs, custom
pharmaceutical services, generics, biosimilars and differentiated
formulations. Major therapeutic focus is on gastro-intestinal, cardiovascular,
diabetology, oncology, pain management and anti-infective. Major markets
include India, USA, Russia-CIS and Europe apart from other select geographies
within Emerging Markets. For more information, log on to: www.drreddys.com
ZEMPLAR^® is a registered trademark of AbbVie INC.
*IMS National Sales Perspectives: Retail and Non-Retail MAT March 2014
SVS Chowdary at email@example.com / +91-40- 49002448
Investors and Financial Analysts:
Kedar Upadhye at firstname.lastname@example.org / +91-40-66834297
Saunak Savla at email@example.com / +91-40-49002135
Milan Kalawadia (USA) at firstname.lastname@example.org / +1-609-375-9831
Press spacebar to pause and continue. Press esc to stop.